AMPH Amphastar Corp: Enterprise Value to EBITDA Ratio
The unwavering trust of clinics in the supply of critical medications confirms the reliability of Amphastar Pharmaceuticals (AMPH). The company relies on the production of high-tech injectable generics, creating high barriers to entry for competitors. Its growth strategy is based on the complexity of sterile manufacturing. The company's EV/EBITDA ratio in a historical context on the GURU.Markets base chart clearly visualizes the market value, where the 8.13 level indicates the state of the parameter.
Comprehensive metric breakdowns and analytics for amphastar.com (AMPH)
- market price and analyst price targets:
- company stock capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
Debt to Equity Amphastar Pharmaceuticals|AMPH - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Amphastar Pharmaceuticals, Inc.|AMPH - Company Aggregate Debts|Debt to Book Capitalization Ratio Amphastar Corp|AMPH - Company Long-Term Liabilities|Company Short-Term Debt Amphastar Pharmaceuticals|Quick Ratio amphastar.com
- financial results and valuation multiples details:
AMPH - Final Profit|Projected Future Earnings Amphastar Pharmaceuticals|AMPH - P/E Multiple|Future Price to Earnings Amphastar Pharmaceuticals|AMPH - Growth-Adjusted Market Cap to Net Income|Enterprise Value to EBITDA Ratio Amphastar Corp|AMPH - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Amphastar Pharmaceuticals|AMPH - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months amphastar.com|AMPH - Earnings per share increase in current year|Expected earnings per share growth for next year Amphastar Pharmaceuticals
Fundamental company analysis:AMPH (Amphastar)
Long-term risk control requires analyzing the Enterprise Value (EV) of the entire business relative to its operating profit, which eliminates distortions from debt and taxes. In the EV/EBITDA multiple history of Amphastar Pharmaceuticals (AMPH), this metric reflects the efficiency of capital-intensive GMP laboratories and FDA certification costs, making it possible to determine whether the current price is fair or signals a systemic crisis of production capacities.
Competitors of Amphastar Pharmaceuticals (AMPH)
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Haleon Group HLN|Kenvue Health (KVUE) - Company Value to EBITDA|VRNA: Enterprise Value to EBITDA Ratio|jyongbio.com - Enterprise Value to Operating Income Before Depreciation Ratio|LGND: EV/EBITDA Multiple|Amneal Pharmaceuticals, Inc. - Business Value to Operating Income Before Depreciation|PRGO (Perrigo Company) - EV/EBITDA Multiple|Company Value to EBITDA Alvotech Biopharmaceuticals ALVO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Liquidia Corporation (LQDA)|GLPG (glpg.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ANIP (ANI Pharmaceuticals, Inc.)|EV/EBITDA Multiple MannKind Corp MNKD|PCRX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ARS Corp (SPRY) - Enterprise Value to EBITDA Ratio|Theravance Biopharma (TBPH) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio AQST (aquestive.com)|SCPH (scPharmaceuticals, Inc.) - EV/EBITDA Multiple|TECX: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple TNXP|EV/EBITDA Multiple sxtchina.com (SXTC)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Eupraxia Pharmaceuticals Inc. EPRX|Total Company Value to Operating Income Before Depreciation Ratio bioharvest.com (BHST)|EXOZ: Enterprise Value to EBITDA Ratio|Oramed Pharmaceuticals - Enterprise Value to Operating Income Before Depreciation Ratio|ENTX: EV/EBITDA Multiple|MindWalk Therapeutics (HYFT) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ABVC BioPharma|CPIX: Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio QNTM (Quantum BioPharma)|FGEN (FibroGen Inc) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Telomir Pharma TELO|RANI (Rani Therapeutics Holdings) - Company Value to Operating Income Before Depreciation Ratio|Synergy CHC Corporation - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation RLYB (Rallybio Corporation)|LEXX: EV/EBITDA Multiple|Pulmatrix Inc (PULM) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pheton Holdings Limited|APM: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lyra Therapeutics, Inc. (LYRA)|Enterprise Value to EBITDA Ratio impactbiomedinc.com IBO|EV/EBITDA Multiple TNFA (TNF Pharmaceuticals, Inc.)|EV/EBITDA Multiple cbdMD Inc. YCBD|PainReform Limited - EV/EBITDA Multiple|Altamira Therapeutics (CYTO) - Enterprise Value to EBITDA Ratio|LIPO: EV/EBITDA Multiple|Company Value to EBITDA optinose.com (OPTN)|Enterprise Value to EBITDA Ratio PIRS|EV/EBITDA Multiple Procaps Group|Enterprise Value to EBITDA Ratio PTPI (Petros)|Enterprise Value to Operating Income Before Depreciation Ratio QLI|EV/EBITDA Multiple SLRN (Acelyrin, Inc.)|Total Company Value to Operating Income Before Depreciation Ratio tffpharma.com (TFFP)
